Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2017–18 Influenza Season

Grohskopf, Lisa A.; Sokolow, Leslie Z.; Broder, Karen R.; Walter, Emmanuel B.; Bresee, Joseph S.; Fry, Alicia M.; Jernigan, Daniel B.

doi:10.1111/ajt.14511

Cited by 88 publications

(86 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, some countries already include QIV next to TIV in their vaccination recommendations, like the US, Canada, and Australia [7][8][9]. The United Kingdom (UK) extended the influenza vaccination program to children using the quadrivalent live-attenuated influenza vaccine (Q-LAIV) [10].…”

Section: Introductionmentioning

confidence: 99%

A systematic review of the health economic consequences of quadrivalent influenza vaccination

Boer

Maanen

Damm

et al. 2017

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

International audienceBackground: Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should overcome a potential reduced vaccine protection due to mismatches between TIV and circulating B viruses. In this study, we systematically reviewed the available literature on health economic evaluations of switching from TIV to QIV.Areas covered: The databases of Medline and Embase were searched systematically to identify health economic evaluations of QIV versus TIV published before September 2016.A total of sixteen studies were included, thirteen cost-effectiveness analyses and three cost-comparisons.Expert commentary: Published evidence on the cost-effectiveness of QIV suggests that switching from TIV to QIV would be a valuable intervention from both the public health and economic viewpoint. However, more research seems mandatory. Our main recommendations for future research include: 1) more extensive use of dynamic models in order to estimate the full impact of QIV on influenza transmission including indirect effects, 2) improved availability of data on disease outcomes and costs related to influenza type B viruses, and 3) more research on immunogenicity of natural influenza infection and vaccination, with emphasis on cross-reactivity between different influenza B viruses and duration of protection

show abstract

Section: Introductionmentioning

confidence: 99%

A systematic review of the health economic consequences of quadrivalent influenza vaccination

Boer

Maanen

Damm

et al. 2017

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…Annual vaccination is the primary means of preventing influenza and its complications. Influenza vaccine is recommended annually from age 6 months during the influenza season, especially for high-risk persons, including those aged >65 years and those with chronic health conditions such as asthma, diabetes, lung disease, heart disease, immunosuppressive disorders, and organ transplant recipients (31).…”

Section: Discussionmentioning

confidence: 99%

Improving influenza vaccination rates of healthcare workers: a multipronged approach in Qatar

Mustafa

Al‐Khal

Maslamani

et al. 2017

East Mediterr Health J

View full text Add to dashboard Cite

We assessed whether an influenza vaccination (IV) campaign was effective at increasing vaccination rate in healthcare workers (HCWs) in 2 hospitals in Doha, Qatar that had no mandatory IV policy. The campaign comprised promotional, educational and vaccine delivery interventions; a dedicated IV team; telephone hotline; free IV with improved access, leadership involvement; incentives; group educational sessions; and reporting/tracking activities. During the 2014/15 influenza season, IV rates according to hospital and HCW category were calculated and compared with the 2 seasons before the intervention. The combined mean rate for IV for both hospitals increased for 2014/15 (64.3%) compared with 2013/14 (37.2%) and 2012/13 (28.4%). There was increased IV uptake among doctors and nurses at each hospital, and the IV rate for the 2 hospitals (59.1 and 69.5%) were higher than in 2013/14 (21.1% and 53.2%) and 2012/13 (17.2% and 39.6%). The findings highlight the importance of improving IV rates among HCWs in hospitals with no mandatory vaccination policies through multicomponent interventions. ‫ر‬

show abstract

“…Since 2004, the US CDC Advisory Committee on Immunisation Practices has recommended that all women who are pregnant or will be pregnant during influenza season should receive inactivated influenza vaccine, regardless of trimester. (14) Pregnant women should not receive a liveattenuated influenza vaccine, which is available as an intranasal spray. In conclusion, H1N1 infection in pregnancy has high maternal morbidity and mortality, hence immediate and aggressive treatment is advised for better maternal and foetal outcome.…”

Section: Pathological Discussionmentioning

confidence: 99%

H1n1 in Pregnancy

Bhavani¹,

Naragoni²,

Gade³

2017

jemds

View full text Add to dashboard Cite

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2017–18 Influenza Season

Abstract: This is an abridged version of the annual update for influenza vaccine administration, which includes recommendations for immunosuppressed hosts.

Cited by 88 publications

References 48 publications

A systematic review of the health economic consequences of quadrivalent influenza vaccination

A systematic review of the health economic consequences of quadrivalent influenza vaccination

Improving influenza vaccination rates of healthcare workers: a multipronged approach in Qatar

H1n1 in Pregnancy

Contact Info

Product

Resources

About